SteriJect Ophthalmic Needles
(RIGHT)
Intravitreal injections have surged with the rise of macular diseases. TSK Laboratory International is addressing this by introducing SteriJect ophthalmic needles. SteriJect is approved for ophthalmic use and engineered for precise delivery of anti-VEGF medications.
TSK’s innovative Low Dead Space (LDS) technology minimises the space within the syringe-hub assembly, preventing air bubbles and reducing waste from sight-saving biologics. The hub geometry drives faster, cleaner flow, while the hard polymer construction ensures safe, secure attachment during injection. Partnering this advanced hub, TSK’s 33G and 34G profiles, with TSKiD technology, require less force for scleral penetration and intravitreal injection, minimising tissue damage, and discomfort. By prioritising patient safety and comfort, TSK is continually elevating the standard of ophthalmic care.
Macular Disease Foundation Australia
For 25 years, Macular Disease Foundation Australia (MDFA) has been the national peak body representing the interests of the estimated 1.9 million Australians who live with a macular disease. As the representative voice, MDFA influences Australian health, aged care, and disability agendas, to improve outcomes for patients, their families, and carers.
The Foundation provides evidence-based leadership to reduce the impact of macular disease through four key pillars of work:
Community awareness and early detection. with eye health professionals to promote regular eye screening. based information and resources, a National Helpline, and other practical service interventions. that reduce the impact of macular disease and improve the quality of life and independence of the MDFA community.
National awareness/engagement campaigns and working in partnership Support for living with macular disease. Free evidence- Advocacy. For initiatives
Research. For a future to prevent and cure macular disease.
Refer your patients with macular disease to MDFA for education and support.
ZEISS Cirrus OCT
(LEFT)
Rather than being a scan protocol, the Advanced Retinal Pigment Epithelium (RPE) Analysis, available on ZEISS Cirrus optical coherence tomography (OCT), is a combination of two algorithms that can be applied to any macular cube scan to measure RPE elevations for mapping drusen and sub-RPE slab illumination. This helps detect areas of geographic atrophy (GA) and their proximity to the fovea, as well as progression or encroachment onto the fovea.
As the Advanced RPE Analysis requires no additional scan captures, it can be
retrospectively applied to any macular cube scan captured on your ZEISS Cirrus OCT.
Furthermore, ZEISS Cirrus Pathfinder represents the latest addition to the ZEISS OCT portfolio. Trained on more than 75,000 B-scans, Cirrus Pathfinder is a decision support tool, powered by artificial intelligence, that detects B-scans in any Cirrus macula cube scan that show signs of pathology, including RPE elevations and atrophy.
Contact: ZEISS Account Manager
Revo HR
(RIGHT)
The Revo HR provides ultra-high-resolution, ultra-widefield optical coherence tomography (OCT) imaging with integrated colour fundus imaging, enabling clinicians to assess retinal structure with one examination.
Operating at 130,000 A-scans per second with axial resolution at the level of 3 μm in tissue (1.4 μm digital), the system provides unique visualisation of retinal layers, taking precision, accuracy, and detection of even the finest lesions to a whole new level.
The Revo HR is an all-in-one device that can be used in a number of ways, such as a full colour fundus camera or as a combo, providing simultaneous OCT and fundus images for high quality OCT imaging, including OCT-A.
Visit: optopol.au